SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Alterity Therapeutics Limited (ATHE) News

Track canonical SquawkNews coverage tagged to ATHE, Alterity Therapeutics Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol ATHE Asset equity Sector Markets 90 days 6 Last 4.67 Updated Aug 12, 2026, 11:05 AM UTC Open live news feed
M ATHE Granted New US Patent Alterity Therapeutics announces granting of new US composition of matter patent for ATH434 EQUITY | Aug 12, 2026, 11:05 AM UTC M ATHE Releases Q4 FY26 Quarterly Cash Flow Report ATHE reports Q4 FY26 cash flow EQUITY | Jul 30, 2026, 11:25 AM UTC L Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy () -- Alterity Therapeutics (ATHE) said Tuesday the US Food and Drug Administration's end-of-phase 2 meeting minutes confirmed agreement on the key elements of the registrational phase 3 trial for ATH434 in multiple syst REGULATION | Jul 07, 2026, 11:45 AM UTC L Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434 Alterity Therapeutics announced that it has received the official meeting minutes from its End-of Phase-2 meeting for ATH434 in Multiple System Atrophy from the FDA. The minutes confirm the elements of the registrational REGULATION | Jul 07, 2026, 11:32 AM UTC L Alterity Therapeutics shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a $16 pr Alterity Therapeutics shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a $16 price target. EQUITY | Jun 30, 2026, 05:45 PM UTC L Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16 Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ: ATHE ) with a Buy rating and announces Price Target of $16. EQUITY | Jun 30, 2026, 01:21 PM UTC